Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) was the target of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,800,000 shares, a drop of 8.6% from the January 15th total of 1,970,000 shares. Based on an average daily trading volume, of 753,800 shares, the days-to-cover ratio is presently 2.4 days.
Health Catalyst Stock Performance
→ Options Expert: “This Trading Strategy Changed The Game!” (From Base Camp Trading)
HCAT opened at $14.44 on Thursday. The business has a fifty day simple moving average of $12.06 and a 200 day simple moving average of $11.11. The company has a market capitalization of $790.59 million, a PE ratio of -4.91 and a beta of 1.28. Health Catalyst has a 1 year low of $6.40 and a 1 year high of $29.96. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.87 and a quick ratio of 4.87.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on HCAT shares. SVB Leerink dropped their target price on Health Catalyst from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 9th. BTIG Research lowered their price target on Health Catalyst to $17.00 in a research report on Tuesday, November 15th. Royal Bank of Canada lowered Health Catalyst from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $19.00 to $9.00 in a research report on Tuesday, October 25th. Piper Sandler lowered their price target on Health Catalyst from $11.00 to $8.00 in a research report on Wednesday, November 9th. Finally, Wells Fargo & Company initiated coverage on Health Catalyst in a research report on Monday, October 31st. They set an “equal weight” rating and a $10.00 price target on the stock. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.53.
Institutional Trading of Health Catalyst
Several institutional investors have recently added to or reduced their stakes in HCAT. Fairfield Bush & CO. acquired a new position in Health Catalyst in the 1st quarter valued at $25,000. US Bancorp DE raised its holdings in Health Catalyst by 256.0% in the 3rd quarter. US Bancorp DE now owns 2,645 shares of the company’s stock valued at $26,000 after acquiring an additional 1,902 shares in the last quarter. Macquarie Group Ltd. acquired a new position in Health Catalyst in the 2nd quarter valued at $26,000. Point72 Hong Kong Ltd acquired a new position in shares of Health Catalyst during the 1st quarter worth $33,000. Finally, Rockefeller Capital Management L.P. raised its holdings in shares of Health Catalyst by 15,253.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 4,606 shares of the company’s stock worth $44,000 after buying an additional 4,576 shares in the last quarter. 90.55% of the stock is currently owned by institutional investors.
About Health Catalyst
Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Health Catalyst, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Health Catalyst wasn’t on the list.
While Health Catalyst currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
